Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: johnsto1 who wrote (33643)	9/3/2000 3:15:47 AM
From: johnsto1	Read Replies (2) \| Respond to of 57584

STEM...was a recommendation in a german stock letter, German stock letter n/a in english Tele Börse: Embryonale Stammzellen werden in wenigen Jahren Krankheiten wie Diabetes, Alzheimer oder Parkinson heilen können. Bereits heute helfen sie bei der Milderung von Nebenwirkungen durch Chemotherapien. Stammzellen haben die Fähigkeit, sich umgehenden Gewebe perfekt anzupassen. Diesen Geheimnissen dieser Zellen auf der Spur ist die US-Biotech-Firma Stemcells. Sie möchte auf den Forschungsergebnissen basierende Therapien für das Nervensystem, die Leber und die Bauchspeicheldrüse entwickweln. Obwohl Stemcells noch längere Zeit keine Gewinne erzielen wird, könnten Forschungserfolge zu einem raschen Kursanstieg führen. Anleger haben bisher auch die Beteiligung in dem Schweizer Biotech-Wert Modex übersehen, der im Juni an die Börse gegangen ist. Die Beteiligung hat aktuel einen Wert von 22 Millionen $ und ist bisher nicht bilanziert. cyto.com Ran the text through the Babel Fish translation engine (babelfish.altavista.com) and this was the result. Not perfect but you sorta get the idea... "Embryonale main cells will be able to heal diseases in few years such as diabetes, Alzheimer or Parkinson. Already today they help with moderating of side effects by chemotherapies. Main cells have the ability to adapt to immediate fabrics perfectly. These secrets of these cells on the track the US Biotech company is Stemcells.* She would like which are based therapies for the nervous system, the liver and the pancreas on the research results entwickweln. Although Stemcells will not obtain still longer time gains, research successes could lead to a rapid improvement in prices. Investors ignored so far also the participation in Swiss Biotech value Modex, which went in June to the stock exchange. The participation has aktuel a value of 22 million $ and is not balanced so far."